Premature ejaculation: definition, assessment and clinical management
Martin J. Steggall
Abstract
Martin J. Steggall
Abstract
Premature ejaculation (PE) is the most common of the male sexual dysfunctions. The prevalence of PE is estimated to be 22.7% of sexually active men, although this may be an underestimation. There are four types of PE, lifelong, acquired, ED‐like PE and normal variability PE. Treatment options include behavioural therapies, selective serotonin reuptake inhibitors (SSRIs) daily or ‘as required’, phosphodiesterase type 5 inhibitors (PDE5I's) (Sildenafil, Tadalafil or Vardenafil), and local anaesthetics/desensitising creams/sprays. The selection of treatment depends on accurate diagnosis of the type of PE and patient preference.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Premature ejaculation (PE) is the most common of the male sexual dysfunctions. The prevalence of PE is estimated to be 22.7% of sexually active men, although this may be an underestimation. There are four types of PE, lifelong, acquired, ED‐like PE and normal variability PE. Treatment options include behavioural therapies, selective serotonin reuptake inhibitors (SSRIs) daily or ‘as required’, phosphodiesterase type 5 inhibitors (PDE5I's) (Sildenafil, Tadalafil or Vardenafil), and local anaesthetics/desensitising creams/sprays. The selection of treatment depends on accurate diagnosis of the type of PE and patient preference.
Key concepts: Premature ejaculation, Vardenafil, Tadalafil, Medicine, Sildenafil, Erectile dysfunction, cGMP-specific phosphodiesterase type 5, Ejaculation